Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 8602
Affinity DataIC50: 1.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 4.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 6.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 7.40nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 8.5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 9.90nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 78nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 3.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 8.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: 9.40E+4nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibitory activities of compounds of the present invention against factor XIa, Xa, XIIa, IXa, VIIa, plasma kallikrein or thrombin were evaluated usi...More data for this Ligand-Target Pair